Key findings from this 48-week, dose-ranging study of 338 adults with obesity: Participants receiving the highest dose (12 mg weekly) lost an average of 24.2% of their body weight in 48 weeks At the 12 mg dose, 100% of participants lost at least 5% of their body weight Approximately 83% of participants on the highest dose lost 15% or more of body weight The weight loss trajectory had not plateaued at 48 weeks, suggesting even greater weight loss with continued treatment To put these numbers in context, here is how retatrutides Phase 2 data compares to the landmark trials of existing medications: The fact that retatrutide achieved the highest percentage of weight loss in the shortest timeframe is what has researchers and patients so excited
Med Microbiol Immunol 208(34):305321 Varnum SM, Streblow DN, Monroe ME, Smith P, Auberry KJ, Paa-Toli L, Wang D, Camp DG, Rodland K, Wiley S et al (2004) Identification of proteins in human cytomegalovirus (HCMV) particles: the HCMV Proteome
Accelerated atrophy of lower leg and foot musclesa follow-up study of long-term diabetic polyneuropathy using magnetic resonance imaging (MRI)
Tumors ot the peripheral nervous system
Theres ongoing preliminary data showing GLP-1s effect on lowering blood pressure and decreasing weight, says Dr
Padam K, Ahamad T, Mishra DP, Khan MF
